In the subgroup of patients developing cancer in the first 3 years, NT-proBNP levels were 519.8 ± 706.5 pg/mL (N = 15) in those with carcinoma and 480.4 ± 143.0 pg/mL (n = 11) in patients developing adenocarcinoma (p = 0.877). The gene discussed is NPPB; the disease is cancer.